Broad-spectrum Rapid Antidote: Varespladib IV to Oral Trial for Snakebite (BRAVIO)
Status:
Not yet recruiting
Trial end date:
2024-04-01
Target enrollment:
Participant gender:
Summary
This is a multicenter,randomized,double-blind, placebo-controlled, phase 2 study designed to
evaluate the safety, tolerability and efficacy of a continuous rate infusion (CRI) of IV
varespladib followed by transition to the oral dosage form, varespladib-methyl, concurrently
with SOC, in participants bitten by venomous snakes.